# Hanmi: longer human testing changes the obesity programme's capital requirement HM15275's first Phase 2 dose advances development without validating the issuer's ambitious weight-loss target. Canonical: https://kgcf.dsmlholdings.com/insights/hanmi-hm15275-phase-two-first-dose/ Published: 2026-10-08 Author: [DSML Holdings LLC](https://www.dsmlholdings.com/) Company: Hanmi Pharmaceutical Event: 2025-12-26 Actual first-patient dosing date reported retrospectively in Hanmi's February 2, 2026 release. ## Reported metrics - Planned long-term dosing: 36 weeks. Phase 2 design reported February 2026; not completed follow-up or observed efficacy.. [Source 1](https://www.hanmipharm.com/about/investor-relations/press/detail-3702.hm) - Expected trial completion: H1 2027. Issuer forecast beyond the research cutoff; not a verified completion date.. [Source 1](https://www.hanmipharm.com/about/investor-relations/press/detail-3702.hm) ## Reported evidence Hanmi reported on February 2, 2026 that the first patient in the US Phase 2 obesity trial of HM15275 was dosed on December 26, 2025. Its release describes 36 weeks of long-term dosing, expected completion in the first half of 2027 and a 2030 commercialization goal. Those future dates and the stated ambition of at least 25% weight reduction are targets, not observed Phase 2 results. The June 10, 2025 research roadmap had targeted Phase 2 initiation in the second half of 2025. ## Investment interpretation First dosing is a meaningful operational transition because it commits the programme to generating more informative human evidence. It also extends cash obligations before commercial access. The economic appeal is potential product differentiation owned by a Korean developer, while the central risk is financing an expensive programme before that differentiation is established. An ambitious biological target should guide research questions, not serve as a present sales assumption. ## Economic assessment Longer dosing brings drug supply, site management, patient follow-up and data analysis costs that cannot be inferred from a press release. The development asset's value depends on safety, tolerability, persistence and body-composition outcomes as well as weight change. A candidate that attracts a partner could shift later financing burdens, but no such transaction is established here. The base capital case therefore needs staged spending and explicit decision points rather than assumed licensing proceeds. ## A Clinical Transition, Not A Commercial Claim The earlier roadmap and subsequent first-dose confirmation provide a coherent sequence: planned initiation followed by a reported actual patient dose. They do not show trial completion. This is more than a conference presentation because the company has crossed into a new operating stage with ongoing patient and supply obligations. The article counts that transition once, not separately as an IND announcement, a roadmap and a later corporate update. A first dose narrows implementation risk but reveals little about the eventual distribution of outcomes. Recruitment and retention may still affect the schedule, while adverse events or protocol changes can alter both cost and evidence quality. Longitudinal studies also create a gap between activity and usable conclusions. Capital should be available to finish the information-generating stage rather than merely to announce its start; interruption could leave incurred costs without an interpretable result. 1. [Hanmi / retrospective first-dose confirmation and Phase 2 plan](https://www.hanmipharm.com/about/investor-relations/press/detail-3702.hm) 2. [Hanmi / earlier dated obesity research and development roadmap](https://www.hanmipharm.com/about/investor-relations/press/detail-2106.hm) ## Differentiation Must Survive The Whole Regimen The issuer's proposed differentiation includes substantial weight reduction and preservation of lean mass. Those are separate clinical questions, and their commercial importance depends on how they are measured alongside tolerability and treatment persistence. A single ambitious percentage cannot capture that profile. The stated at-least-25% objective is not an observed Phase 2 endpoint result and is not used here as a revenue or competitive-share input. A future buyer or licensee would also examine administration, manufacturing consistency, dose escalation and the burden on prescribers and patients. A product with favorable headline efficacy but difficult long-term use could require a different positioning than its initial research narrative suggests. Conversely, a less dramatic average result could still have a useful segment if the overall benefit-risk and delivery profile were distinctive. These possibilities support an evidence-led product assessment rather than a binary ranking from promotional targets. 1. [Hanmi / retrospective first-dose confirmation and Phase 2 plan](https://www.hanmipharm.com/about/investor-relations/press/detail-3702.hm) 2. [Hanmi / earlier dated obesity research and development roadmap](https://www.hanmipharm.com/about/investor-relations/press/detail-2106.hm) ## Development Costs Are Front-Loaded Human development spends cash while uncertainty remains substantial. Manufacturing clinical supply and maintaining trial quality are commitments even when the final result disappoints. Later pivotal work, regulatory preparation and commercial capacity would add new funding stages. The company's completion and commercialization goals describe a desired route, not an available financing package. A lender should not assume that future product receipts will arrive before existing obligations become payable. Staged capital can still be productive if it purchases decisions that materially improve the next funding terms. The important questions are the cost to reach a robust dataset, the point at which the programme can be stopped or partnered and the residual value of developed know-how. A disciplined programme budget should distinguish reusable platform spending from candidate-specific costs. That distinction helps avoid financing every development expense as though it were readily transferable collateral. 1. [Hanmi / retrospective first-dose confirmation and Phase 2 plan](https://www.hanmipharm.com/about/investor-relations/press/detail-3702.hm) ## Retained Rights And A Possible Partner The source evidence concerns Hanmi's development programme, not an announced sale of the asset. Retained rights can preserve strategic flexibility, but ownership also leaves more financing and execution exposure with the developer. A future licensing proposal would need to allocate territories, indications, manufacturing, trial sponsorship and improvements. Without those details, assigning a hypothetical upfront payment is not a reasonable way to close the cash forecast. Korean pharmaceutical development can benefit from local scientific capabilities while testing abroad for a broader evidence base. The relevant international advantage is neither the trial's US address alone nor the size of a generic global obesity market. It is the ability to deliver evidence and product quality acceptable to counterparties and regulators while retaining a defensible claim on subsequent economics. That claim may eventually be a royalty, supply contribution or direct commercial margin; the present sources do not select one. 1. [Hanmi / retrospective first-dose confirmation and Phase 2 plan](https://www.hanmipharm.com/about/investor-relations/press/detail-3702.hm) 2. [Hanmi / earlier dated obesity research and development roadmap](https://www.hanmipharm.com/about/investor-relations/press/detail-2106.hm) ## China - DSML comparison Chinese development programmes are a competitive comparison, not reported partners or customers for HM15275. ## Japan - DSML comparison Japanese regulatory and commercial entry would require separate evidence and rights; none is established by first US dosing. ## Other Asia - Reported connection Hanmi is the Korean developer. Korean scientific ownership is relevant, but no new regional launch is reported here. ## United States - Reported connection The reported Phase 2 trial is in the United States. Clinical activity is not FDA marketing authorization. ## Europe - DSML comparison European metabolic-drug developers offer a capital and product comparison; a European licence is not disclosed. ## Counterpoint Waiting for complete commercial certainty would prevent novel drug development. A sufficiently funded Phase 2 programme can create valuable evidence and negotiating options. The counterargument is not against research spending itself, but against capitalizing issuer targets as established differentiation before durable human results and a credible next-stage funding route exist. ## Underwriting questions 1. What fully funded budget reaches an interpretable Phase 2 dataset? 2. Which safety, persistence and body-composition results determine the next decision? 3. What rights and obligations would a partner receive, and what remains with Hanmi? ## Primary sources 1. [Hanmi / retrospective first-dose confirmation and Phase 2 plan](https://www.hanmipharm.com/about/investor-relations/press/detail-3702.hm) (2026-02-02) 2. [Hanmi / earlier dated obesity research and development roadmap](https://www.hanmipharm.com/about/investor-relations/press/detail-2106.hm) (2025-06-10)